Published online Jul 16, 2021. doi: 10.12998/wjcc.v9.i20.5470
Peer-review started: April 1, 2021
First decision: April 13, 2021
Revised: April 25, 2021
Accepted: April 26, 2021
Article in press: April 26, 2021
Published online: July 16, 2021
Processing time: 96 Days and 23 Hours
Spinal metastasis is common in patients with cancer. The optimal treatment for metastatic spine tumors should be selected based on prognostic predictions.
In order to find influential factors that guide treatment decision making, the study examined spinal cord injury function, the incidence of metastatic spinal cord compression (MSCC), spinal instability neoplastic score (SINS), survival and factors associated with prognosis in patients with metastatic spinal cancer.
To examine the factors for predicting the prognoses and its predictive value in patients with metastatic spinal cancer.
A study was performed involving 109 patients with metastatic spinal cancer. Clinical, sociodemographic and prognostic data were extracted. They were classified into two groups: Patients with survival of 3 years or over 3 years were enrolled in a survival group and those with survival under 3 years were enrolled in a death group. The incidence of MSCC and SINS and Frankel spinal cord injury functional classification scale score and revised Tokuhashi score were compared between the two groups. The prognostic significance of factors influencing the prognosis of patients with metastatic spinal cancer was analyzed including general information, Frankel spinal cord injury functional classification scale score, SINS score and revised Tokuhashi score.
There were significant differences in outcomes of patients with metastatic spinal cancer of different age, treatment methods, number of spinal tumors, Karnofsky performance score, Frankel spinal cord injury functional classification scale score, SINS score and revised Tokuhashi score, indicating that these factors have significant effects on the prognosis of patients with metastatic spinal cancer.
The detection of the above important factors may be useful for aiding the selection of appropriate treatment modalities for metastatic spinal cancer.
The subjects of the current study were restricted to patients with some cancer types and patients undergoing surgical treatment. Additional clinical studies with larger sample sizes investigating extra novel factors are required to validate further these findings.